This research demonstrates enhanced bioimaging in immunodeficient mice with ovarian cancer, suggesting benefits for antitumor drug development.
The method of intravital bioimaging based on luminescence occupies an important place in the development and testing of antitumor drugs on model animals and is an essential part of preclinical studies. Bioimaging based on luminescent systems, compared with fluorescent bioimaging, provides a high signal-to-noise ratio, which justifies the development of cell lines, that stably express luciferase genes for subsequent use in model animals. The work describes the creation of a stable cell line SKOV3.ip1-NanoLuc constitutively expressing the NanoLuc luciferase gene. The developed cell line was shown to be effective for intravital luminescence bioimaging of immunodeficient animals with deep-seated intraperitoneal tumors, which can be considered as a model of late-stage ovarian cancer.
No takes yet. Share an insight, caveat, or question.
E. I. Shramova (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: